^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BC3448

    i
    Other names: BC3448
    Associations

    News

    Trials
    Company:
    Wuxi Biocity
    Drug class:
    EGFR inhibitor, CD3 agonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC (IASLC-WCLC 2023)
    Additionally, the total protein of H1975-OR treated with BC3448 or Panitumumab for 2 days was subsequently subjected for Sally Sue Simple Western analysis. BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a promising agent for Osimertinib-resistant NSCLC.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • GZMB (Granzyme B)
    |
    EGFR H1975
    |
    Tagrisso (osimertinib) • Vectibix (panitumumab) • BC3448